Biophytis S.A. (ALBPS.PA)
EUR 0.33
(0.92%)
EUR 0.33
(0.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.8 Million EUR | 41.65% |
| 2022 | -23.03 Million EUR | 11.78% |
| 2021 | -26.5 Million EUR | -88.48% |
| 2020 | -13.66 Million EUR | 9.69% |
| 2019 | -15.42 Million EUR | -15.28% |
| 2018 | -13.63 Million EUR | -41.35% |
| 2017 | -9.81 Million EUR | -24.16% |
| 2016 | -7.77 Million EUR | -149.86% |
| 2015 | -4.97 Million EUR | -373.24% |
| 2014 | -704.63 Thousand EUR | -40.72% |
| 2013 | -467.99 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.13 Million EUR | 0.0% |
| 2024 Q1 | -2.13 Million EUR | 42.3% |
| 2023 Q2 | -3.2 Million EUR | 0.0% |
| 2023 Q3 | -3.69 Million EUR | -15.45% |
| 2023 FY | - EUR | 36.21% |
| 2023 Q4 | -3.69 Million EUR | 0.0% |
| 2023 Q1 | -3.2 Million EUR | 43.14% |
| 2022 Q2 | -14.38 Million EUR | -144.49% |
| 2022 Q1 | -5.88 Million EUR | 67.8% |
| 2022 FY | - EUR | 11.78% |
| 2022 Q3 | -5.63 Million EUR | 60.84% |
| 2022 Q4 | -5.63 Million EUR | 0.0% |
| 2021 Q4 | -18.27 Million EUR | -126.76% |
| 2021 FY | - EUR | -88.48% |
| 2021 Q1 | -5.19 Million EUR | 34.42% |
| 2021 Q2 | -12.56 Million EUR | -141.97% |
| 2021 Q3 | -8.06 Million EUR | 35.83% |
| 2020 Q4 | -7.91 Million EUR | -138.18% |
| 2020 Q1 | -3.53 Million EUR | 49.85% |
| 2020 Q3 | -3.32 Million EUR | 63.43% |
| 2020 Q2 | -9.08 Million EUR | -157.41% |
| 2020 FY | - EUR | 9.69% |
| 2019 Q1 | -3.39 Million EUR | 15.32% |
| 2019 FY | - EUR | -15.28% |
| 2019 Q4 | -7.04 Million EUR | -137.04% |
| 2019 Q3 | -2.97 Million EUR | 51.32% |
| 2019 Q2 | -6.1 Million EUR | -79.49% |
| 2018 Q3 | -4.05 Million EUR | -49.67% |
| 2018 Q2 | -2.7 Million EUR | 5.12% |
| 2018 Q1 | -2.85 Million EUR | -1.1% |
| 2018 FY | - EUR | -41.35% |
| 2018 Q4 | -4.01 Million EUR | 0.96% |
| 2017 Q2 | -2.02 Million EUR | 0.0% |
| 2017 Q3 | -2.82 Million EUR | -39.1% |
| 2017 Q4 | -2.82 Million EUR | 0.0% |
| 2017 FY | - EUR | -24.16% |
| 2017 Q1 | -2.02 Million EUR | 2.15% |
| 2016 Q4 | -2.07 Million EUR | 0.0% |
| 2016 Q3 | -2.07 Million EUR | -14.33% |
| 2016 Q1 | -1.81 Million EUR | -7.5% |
| 2016 FY | - EUR | -149.86% |
| 2016 Q2 | -1.81 Million EUR | 0.0% |
| 2015 Q1 | -801.5 Thousand EUR | -347.13% |
| 2015 Q2 | -801.5 Thousand EUR | 0.0% |
| 2015 Q4 | -1.68 Million EUR | 0.0% |
| 2015 FY | - EUR | -373.24% |
| 2015 Q3 | -1.68 Million EUR | -110.54% |
| 2014 Q4 | -179.25 Thousand EUR | 0.0% |
| 2014 Q2 | -153.41 Thousand EUR | 0.0% |
| 2014 Q1 | -153.41 Thousand EUR | 0.0% |
| 2014 FY | - EUR | -40.72% |
| 2014 Q3 | -179.25 Thousand EUR | -16.84% |
| 2013 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -319.574% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 89.637% |
| Adocia SA | -22.73 Million EUR | 39.275% |
| Aelis Farma SA | -6.34 Million EUR | -117.489% |
| Advicenne S.A. | -6.24 Million EUR | -121.076% |
| genOway Société anonyme | 6.35 Million EUR | 317.36% |
| IntegraGen SA | -52.5 Thousand EUR | -26191.831% |
| Medesis Pharma S.A. | -3.84 Million EUR | -259.023% |
| Neovacs S.A. | -8.44 Million EUR | -63.37% |
| NFL Biosciences SA | -4.04 Million EUR | -240.898% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 19132.125% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -380.393% |
| Sensorion SA | -22.31 Million EUR | 38.137% |
| Theranexus Société Anonyme | -7.38 Million EUR | -86.863% |
| TME Pharma N.V. | -5.07 Million EUR | -172.161% |
| Valbiotis SA | -6.95 Million EUR | -98.476% |
| TheraVet SA | -517.33 Thousand EUR | -2568.285% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 27.025% |
| argenx SE | -199.5 Million EUR | 93.081% |
| BioSenic S.A. | -6.79 Million EUR | -103.119% |
| Celyad Oncology SA | -7.76 Million EUR | -77.818% |
| DBV Technologies S.A. | -79.53 Million EUR | 82.643% |
| Galapagos NV | 51.03 Million EUR | 127.047% |
| Genfit S.A. | -28.05 Million EUR | 50.79% |
| GeNeuro SA | -14.31 Million EUR | 3.588% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 7.85% |
| Innate Pharma S.A. | -7.57 Million EUR | -82.159% |
| Inventiva S.A. | -101.84 Million EUR | 86.446% |
| MaaT Pharma SA | -19.74 Million EUR | 30.071% |
| MedinCell S.A. | -20.04 Million EUR | 31.138% |
| Nanobiotix S.A. | -34.01 Million EUR | 59.423% |
| Onward Medical N.V. | -35.23 Million EUR | 60.822% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -211.367% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 40.669% |
| Oxurion NV | -16.72 Million EUR | 17.485% |
| Pharming Group N.V. | 4.98 Million EUR | 377.135% |
| Poxel S.A. | -12.17 Million EUR | -13.343% |
| GenSight Biologics S.A. | -21.73 Million EUR | 36.475% |
| Transgene SA | -27.02 Million EUR | 48.919% |
| Financière de Tubize SA | 184.57 Thousand EUR | 7578.965% |
| UCB SA | 1.26 Billion EUR | 101.088% |
| Valneva SE | -64.51 Million EUR | 78.604% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 51.314% |